Video

Given the therapies -- statins, SGLT2 inhibitors, antihypertensive agents, etc. -- we can use to reduce CV risk in T2D patients, where do you see liraglutide fitting in based on LEADER?

Name: Given the therapies -- statins, SGLT2 inhibitors, antihypertensive agents, etc. -- we can use to reduce CV risk in T2D patients, where do you see liraglutide fitting in based on LEADER?
Uploaded: 2017-03-20T00:00:00+00:00
Description: Given the multiple diabetes- and non-diabetes-focused therapies — statins, SGLT2 inhibitors, antihypertensive agents, etc. — we can use to reduce CV risk in patients with T2D, where do you see liraglutide fitting in based on LEADER?

Published: March 20, 2017

Given the therapies -- statins, SGLT2 inhibitors, antihypertensive agents, etc. -- we can use to reduce CV risk in T2D patients, where do you see liraglutide fitting in based on LEADER?

Given the multiple diabetes- and non-diabetes-focused therapies — statins, SGLT2 inhibitors, antihypertensive agents, etc. — we can use to reduce CV risk in patients with T2D, where do you see liraglutide fitting in based on LEADER?

Overview

CLICK HERE FOR CME CREDIT

Created by

Presenter

Vivian Fonseca, MD

Professor of Medicine and Pharmacology
Tullis Tulane Alumni Chair in Diabetes
Chief, Section of Endocrinology
Tulane University Health Sciences Center
Past President, Science and Medicine
American Diabetes Association

Related Videos

Video

What are the clinical implications of the fact that liraglutide’s benefits were seen in a high risk population that was already on maximal therapy for CV risk reduction?

Video

Since the reduction in non-fatal MI in the LEADER trial was not significant enough to explain the impressive 22% in CV mortality, what factors do you think might have played a role?

Video

What did we learn about glycemic control achieved with liraglutide in LEADER? Might the differences in glycemic exposure and other metabolic factors explain the reduction on kidney disease?

What did we learn about the degree of glycemic control achieved with liraglutide in the LEADER trial? And might the differences in glycemic exposure and other metabolic factors explain the reduction on kidney disease?

Video

Can you drill down into the results of LEADER, including primary end points and breakdown of MACE events? What did we learn about the dose of liraglutide required for CV outcome improvement?

Video

What is the foundational importance of the LEADER trial and what makes it different and, perhaps, more significant than previous trials evaluating strategies for CV risk reduction in T2D?